Walleye Capital’s Acceleron Pharma XLRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-22,854
Closed -$3.93K 2520
2021
Q3
$3.93K Buy
+22,854
New +$2.99M 0.11% 121
2020
Q2
Sell
-2,193
Closed -$197K 1102
2020
Q1
$197K Buy
+2,193
New +$170K 0.04% 445
2019
Q2
Sell
-2,480
Closed -$103K 2185
2019
Q1
$115K Buy
+2,480
New +$109K 0.02% 995

Walleye Capital's XLRN Position: Q4 2021 in Review

Walleye Capital sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 22,854 shares — an estimated $3.93K sold.

Walleye Capital first reported a position in XLRN in Q1 2019 and held it in 3 quarters. The position peaked at $197K in Q1 2020. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

  • Walleye Capital reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
  • Walleye Capital sold 22,854 Acceleron Pharma shares in Q4 2021, an estimated $3.93K.
  • Walleye Capital first reported a position in Acceleron Pharma in Q1 2019 and held it in 3 quarters.
  • Walleye Capital's Acceleron Pharma position peaked at $197K in Q1 2020.
  • 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Walleye Capital's 13F filing for Q4 2021, filed 3 Mar 2022.